Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.

Rory J McCrimmonKaren PalmerAbdul Jabbar Omar AlsalehElisheva LewAmar Puttanna

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)

iGlarLixi provides improved QALY outcomes at an acceptable cost compared with premix BIAsp 30, with an ICER below the threshold generally considered acceptable by UK authorities. In people with T2D, iGlarLixi is a simple, cost-effective option for advancing therapy of BI, with fewer daily injections than premix BIAsp 30.

Keyphrases

type diabetes
cross sectional
glycemic control
physical activity
platelet rich plasma
mesenchymal stem cells
metabolic syndrome
skeletal muscle
bone marrow